期刊文献+

氟伐他汀等他汀类药物通过降低低密度脂蛋白水平减少心血管疾病风险的研究进展 被引量:2

Research Progress on Fluvastatin and other Statins Lowering LDL-C to Reduce Cardiovascular Risk
下载PDF
导出
摘要 低密度脂蛋白胆固醇是心血管疾病的主要原因之一,现在有大量证据支持降低低密度脂蛋白胆固醇可以降低心血管疾病的发病率和死亡率。本文将综述关于低密度脂蛋白胆固醇作为心血管疾病的终身性危险因子和作为氟伐他汀等他汀类药物治疗靶点的研究进展。 Low-density lipoprotein cholesterol(LDL-C)is one major cause of cardiovascular disease,and there is now overwhelming evidence to support lowering LDL-C to reduce cardiovascular morbidity and mortality.In this review,we summarizes on current developments in the understanding of LDL-C as lifelong risk factor and treatment targets to reduce cardiovascular risk by lowering LDL-C with fluvastatin and other statins,which are a class of drugs frequently prescribed to lower cholesterol.
作者 李琳 LI Lin(Department of Endocrinology,PLA Rocket Force Characteristic Medical Center,Beijing 100088,China)
出处 《药品评价》 CAS 2020年第22期12-14,共3页 Drug Evaluation
关键词 氟伐他汀 低密度脂蛋白胆固醇 心血管疾病 Fluvastatin LDL-C Cardiovascular Disease
  • 相关文献

参考文献1

二级参考文献10

  • 1曾群英,高修仁,廖新学,冷秀玉,刘东红,陈国伟,王妍,胡舜英.不同剂量氟伐他汀早期治疗急性冠状动脉综合征[J].岭南心血管病杂志,2005,11(2):98-103. 被引量:1
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
  • 3Ballantyne CM,Pazzucconi F,Xavier P. Efficacy and tolerability of fluvastatin extended-release delivery system:A pooled analysis[J].Clinical Therapeutics,2001,(02):177-192.doi:10.1016/S0149-2918(01)80001-1.
  • 4Scripture CD,Pieper JA. Clinical pharmacokinetics of fluvastatin[J].Clinical Pharmacokinetics,2001,(04):263-281.
  • 5Tse FL,Nickerson DF,Yardley WS. Binding of fluvastatin to blood cells and plasma proteins[J].Journal of Pharmaceutical Sciences,1993.942-947.
  • 6Silva MA,Swanson AC,Gandhi PJ,et a1. Statin-related adverse events:A meta-analysis[J].Clinical Therrapeutics,2006,(01):26-35.
  • 7Kopplow K,Letschert K,Kongjg J. Human hepatobiliary transport of organic anions analyzed by quadruple-trasfected cells[J].Molecular Pharmacology,2005,(04):1031-1038.
  • 8Kalliokoski A,Niemi M. Impact of OATP transporters on pharmacokinetics[J].British Journal of Pharmacology,2009.693-705.
  • 9McKenny JM,Davidson MH,Jacobson TA. Fina1 conclusions and recommendations of the natioral lipid association statin safety assessment task force[J].American Journal of Cardiology,2006,(suppl):89C-94C.
  • 10Serruys PW,de Feyter P,Macaya C. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention:a randomized controlled trial[J].Journal of the American Medical Association,2002,(24):3215-3222.

同被引文献33

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部